We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.
Main Menu

Professor David Dearnaley

Team leader

The alt text
Professor David Dearnaley has been central to the development of intensity modulated radiotherapy – a new radiotherapy technique that reduces damage to healthy tissue. He is currently running several trials for treating prostate and testicular cancer and is investigating new image-guided radiotherapy techniques. Team: Clinical Academic Radiotherapy (Dearnaley)

T 0208 661 3271

Biography

David Dearnaley joined The Institute of Cancer Research (ICR) almost 30 years ago. He is developing and assessing new radiotherapy techniques and helping to care for patients with urological cancer, including cancers of the prostate, testes and bladder. He is a Professor of Uro-Oncology and Honorary Consultant Clinical Oncologist at the ICR and The Royal Marsden NHS Foundation Trust

Professor Dearnaley has been central to the development of better radiotherapy treatments for prostate cancer, including a high-tech method called IMRT which uses 3D modelling to target radiation precisely to the tumour shape. It reduces damage to healthy tissue, which means higher doses can be given without increasing side effects.

Professor Dearnaley first began treating patients using IMRT nine years ago and the technology has since been adopted across the country. He is now running a major trial in 35 of Britain’s 58 treatment centres looking at whether more patients can be cured without an increase in side-effects by giving larger doses of radiation but in fewer treatments.

In the future, he would like to make further improvements in radiotherapy techniques for prostate cancer and get these introduced nationally, something he is hopeful of achieving.
He is running several other patient trials involving prostate and testicular cancer including systemic treatments with hormonal treatments and chemotherapy and new image guided techniques to further improve the accuracy of radiotherapy. Additional projects include studies of new molecular and genetic markers to predict the outcome following radiotherapy.